Remission: The Facts, What is Possible

Remission: The Facts, What is Possible

Ulrich Specks, MD, talks about a topic that is critically important to patients with vasculitis — remission. He begins with the main question of how remission is clinically defined, and then explores maintaining/managing remission once it has been achieved.

What does it mean to be in remission 01:17
What does remission mean to physicians 05:13
“Remission” as Clinical Trial Outcomes Measure 08:44
What are the keys to a better outcome 11:40
Ultimate Management Dilemma in ANCA-associated Vasculitis 13:06
How do we maintain remission? 14:00
How do we monitor you once you achieve remission 15:55
Drugs that are used to maintain remission 18:26
The MAINRITSAN Trial 19:50
How can we improve remission maintenance 20:09
The Physician Global Assessment (PGA) as a biomarker 20:57
Rituximab used for remission maintenance comes in two forms 25:04
Summary of key points on remission 27:52

FAQ

Here’s an option if you don’t watch the full video.
Below are short, topic-specific segments from this lecture.

What is the definition of remission in vasculitis?

What are the keys to better outcomes?

How do you maintain remission?

What drugs are used in remission maintenance?

What is individualized re-treatment?

What are the key points about remission?

Ulrich Specks, MD · Chair, Division of Pulmonology and Critical Care, Mayo Clinic Rochester; and Professor of Medicine, Mayo Clinic College of Medicine & Sciences, Rochester, Minnesota
Dr. Specks is Chair of the Division of Pulmonary & Critical Care Medicine and has had a long-standing interest in ANCA-associated vasculitis. These diseases have been the focus of his clinical activities as well as widely published research. He’s made substantial contributions to the understanding of the pathogenesis of ANCA-associated vasculitis, the refinement of ANCA test methodologies, and our understanding of optimal clinical applications of ANCA testing. Dr. Specks is an expert for respiratory manifestations of vasculitis and has had a keen interest in novel therapies for ANCA-associated vasculitis. He introduced rituximab to the treatment of ANCA-associated vasculitis and was co-principal investigator of the Rituximab for ANCA-associated Vasculitis (RAVE) trial.